Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5718 IR · 1 trial · 1 indication
Assessment of AUC of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.
Assessment of AUC(0-last) of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.
Assessment of Cmax of rosuvastatin when administered alone and in combination with AZD5718 in healthy volunteers.
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 10 mg rosuvastatin tablet alone (fasting state) |
| Treatment B | EXPERIMENTAL | 10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state) |
| Treatment C | EXPERIMENTAL | 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state) |
| Treatment D | EXPERIMENTAL | 200 mg of AZD5718 oral suspension 50 mg/mL (fasting state) |
| Treatment E | EXPERIMENTAL | 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state) |
| Name | Type | Description |
|---|---|---|
| AZD5718 IR tablet | DRUG | - |
| AZD5718 oral suspension | DRUG | - |
| Rosuvastatin tablet | DRUG | - |
Inclusion Criteria: For inclusion in the study, subjects should fulfill the following criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male and/or female subjects (of non childbearing potential) aged 18 to 50 years (inclusive) ...
AZD5718 IR is an investigational small molecule being developed for high risk coronary artery disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in a clinical trial setting to evaluate its effects and pharmacokinetics in patients with this condition.
AZD5718 IR is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical research on this investigational drug for the treatment of high risk coronary artery disease.
AZD5718 IR is currently in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The Phase 1 trial has been completed, and the drug remains under investigation for its potential use in high risk coronary artery disease.
AZD5718 IR has one completed Phase 1 clinical trial registered under NCT02963116. This study evaluated the effect of AZD5718 on the pharmacokinetics of rosuvastatin and compared the relative bioavailability of AZD5718 oral suspension versus the immediate release tablet. The trial enrolled 12 participants in the United Kingdom.
AZD5718 IR refers to the immediate release tablet formulation of the drug AZD5718, while AZD5718 oral suspension is a different formulation. A clinical trial has been conducted to measure the relative bioavailability of the oral suspension compared to the immediate release tablet, indicating they are distinct formulations of the same drug.